Liver Cirrhosis

Combined therapies improve outcomes in phase II trial of cancer patients

Published in Hepatitis Weekly, February 24th, 2003

by Sonia Nichols, senior medical writer - Medical researchers at the University of Texas M.D. Anderson Cancer Center say a combination of interferon (IFN)-alfa-2b and fluorouracil (FU) improves outcomes in liver cancer patients and can be tolerated by those with underlying liver cirrhosis.

According to Yehuda Z. Patt and colleagues, cirrhosis is often seen in patients diagnosed with hepatocellular carcinoma (HCC), but its presence also means that certain chemotherapies can not be used. FU and IFN-alfa-2b may be appropriate for treating those patients, based on the results of a phase II clinical trial.

For the trial, physicians prescribed continuous...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry